Update on intravenous immunoglobulins (IVIG) mechanisms of action and off label use in autoimmune diseases

Current Pharmaceutical Design

Volumn 17, Issue 29, 2011, Pages 3166-3175

  Katz, Uriel ^a   Shoenfeld, Yehuda ^a,b   Zandman Goddard, Gisele ^a,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Intravenous Immunoglobulins; IVIg; Molecular mechanisms; Off label

Indexed keywords

CD22 ANTIGEN; DIMER; FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; SIALOPROTEIN; SUPERANTIGEN;

ACUTE KIDNEY FAILURE; ANAPHYLAXIS; ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTHRITIS; ARTICLE; ASEPTIC MENINGITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACKACHE; BEHCET DISEASE; BLOOD PRESSURE; BULLOUS SKIN DISEASE; CHEST TIGHTNESS; CHILL; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; ENDOCRINE OPHTHALMOPATHY; FATIGUE; FEVER; FLUSHING; HEADACHE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MALAISE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OFF LABEL DRUG USE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SJOEGREN SYNDROME; SKIN DEFECT; SKIN FIBROSIS; STIFF MAN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TACHYCARDIA; THROMBOEMBOLISM; TREATMENT INDICATION; URTICARIA; VOMITING;

ANIMALS; AUTOIMMUNE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; OFF-LABEL USE; RISK FACTORS; THROMBOSIS;

EID: 80055093311     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798157540     Document Type: Article

References (115)

1. Cherin P, Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs 2010; 24: 211-23.
2. Gurcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev 2010; 9: 553-9.
3. Stein MR. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. Postgrad Med 2010; 122: 176-84.
4. Kivity S, Katz U, Daniel N, Nussinovitch U, Papageorgiou N, Shoenfeld Y. Evidence for the use of intravenous immunoglobulins-- a review of the literature. Clin Rev Allergy Immunol 2010; 38: 201-69.
5. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-31.
6. Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005; 38: 123-37.
7. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117: S525-53.
8. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am 2008; 28: 765-78, viii.
9. Djoumerska IK, Tchorbanov AI, Donkova-Petrini VD, Pashov AD, Vassilev TL. Serum IgM, IgG and IgA block by F(ab')-dependent mechanism the binding of natural IgG autoantibodies from therapeutic immunoglobulin preparations to self-antigens. Eur J Haematol 2005; 74: 101-10.
10. Shoenfeld Y, Rauova L, Gilburd B, et al. Efficacy of IVIG affinitypurified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002; 14: 1303-11.
11. Krause I, Blank M, Levi Y, Koike T, Barak V, Shoenfeld Y. Antiidiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression. Clin Exp Immunol 1999; 117: 190-7.
12. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227-8.
13. Reed E, Hardy M, Benvenisty A, et al. Effect of antiidiotypic antibodies to HLA on graft survival in renal-allograft recipients. N Engl J Med 1987; 316: 1450-5.
14. Reed E, Rouah C, Hsu D, et al. Anti-idiotypic antibodies regulate the immune response to HLA in heart allograft recipients. Transplant Proc 1989; 21: 463-4.
15. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990; 323: 705-12.
16. Baerenwaldt A, Biburger M, Nimmerjahn F. Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol 2010; 6: 425-34.
17. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins-- understanding properties and mechanisms. Clin Exp Immunol 2009; 158 (Suppl 1): 2-13.
18. Ibanez C, Montoro-Ronsano JB. Intravenous immunoglobulin preparations and autoimmune disorders: mechanisms of action. Curr Pharm Biotechnol 2003; 4: 239-47.
19. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29: 608-15.
20. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
21. Rhoades CJ, Williams MA, Kelsey SM, Newland AC. Monocytemacrophage system as targets for immunomodulation by intravenous immunoglobulin. Blood Rev 2000; 14: 14-30.
22. Newland AC, Treleaven JG, Minchinton RM, Waters AH. Highdose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet 1983; 1: 84-7.
23. Sater RA, Rostami A. Treatment of Guillain-Barre syndrome with intravenous immunoglobulin. Neurology 1998; 51: S9-15.
24. Howard JF, Jr. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 1998; 51: S30-6.
25. Jin F, Balthasar JP. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol 2005; 66: 403-10.
26. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98: 1095-9.
27. Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994; 139: 159-72.
28. Vassilev TL, Bineva IL, Dietrich G, Kaveri SV, Kazatchkine MD. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun 1995; 8: 405-13.
29. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998; 51: S2-8.
30. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313: 670-3.
31. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320: 373-6.
32. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 2008; 105: 19571-8.
33. Seite JF, Cornec D, Renaudineau Y, Youinou P, Mageed RA, Hillion S. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes. Blood 2010; 116: 1698-704.
34. von Gunten S, Simon HU. Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg). Autoimmun Rev 2008; 7: 453-6.
35. Nikolova KA, Tchorbanov AI, Djoumerska-Alexieva IK, Nikolova M, Vassilev TL. Intravenous immunoglobulin up-regulates the expression of the inhibitory FcgammaIIB receptor on B cells. Immunol Cell Biol 2009; 87: 529-33.
36. Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 2007; 1110: 426-32.
37. Seite JF, Shoenfeld Y, Youinou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev 2008; 7: 435-9.
38. Doi M, Takeda T, Sakurai Y, et al. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease. J Investig Allergol Clin Immunol 2010; 20: 413-8.
39. Bayry J, Fournier EM, Maddur MS, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2011; 36: 9-15.
40. Kessel A, Peri R, Haj T, et al. IVIg Attenuates TLR-9 Activation in B Cells from SLE Patients. J Clin Immunol 2011; 31: 30-8.
41. Ephrem A, Chamat S, Miquel C, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 2008; 111: 715-22.
42. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007; 179: 5571-5.
43. Achiron A, Barak Y, Goren M, et al. Intravenous immune globulin in multiple sclerosis: clinical and neuroradiological results and implications for possible mechanisms of action. Clin Exp Immunol 1996; 104 Suppl 1: 67-70.
44. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide Tregitopes. Blood 2008; 112: 3303-11.
45. Konrad S, Baumann U, Schmidt RE, Gessner JE. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages. Br J Haematol 2006; 134: 345-7.
46. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513-33.
47. von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU. Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006; 108: 4255-9.
48. von Gunten S, Vogel M, Schaub A, et al. Intravenous immunoglobulin preparations contain anti-Siglec-8 autoantibodies. J Allergy Clin Immunol 2007; 119: 1005-11.
49. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758-65.
50. Crow AR, Brinc D, Lazarus AH. New insight into the mechanism of action of IVIg: the role of dendritic cells. J Thromb Haemost 2009; 7 Suppl 1: 245-8.
51. Press R, Nennesmo I, Kouwenhoven M, Huang YM, Link H, Pashenkov M. Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 2005; 159: 165-76.
52. Tha-In T, Metselaar HJ, Tilanus HW, et al. Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood 2007; 110: 3253-62.
53. Aoki K, Kajiura S, Matsumoto Y, et al. Preconceptional naturalkiller-cell activity as a predictor of miscarriage. Lancet 1995; 345: 1340-2.
54. Perricone R, Di Muzio G, Perricone C, et al. High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins. Am J Reprod Immunol 2006; 55: 232-9.
55. van den Heuvel MJ, Peralta CG, Hatta K, Han VK, Clark DA. Decline in number of elevated blood CD3(+) CD56(+) NKT cells in response to intravenous immunoglobulin treatment correlates with successful pregnancy. Am J Reprod Immunol 2007; 58: 447-59.
56. Shoenfeld Y, Fishman P. Gamma-globulin inhibits tumor spread in mice. Int Immunol 1999; 11: 1247-52.
57. Frank MM, Miletic VD, Jiang H. Immunoglobulin in the control of complement action. Immunol Res 2000; 22: 137-46.
58. Basta M. Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition. Mol Immunol 2008; 45: 4073-9.
59. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991; 77: 376-80.
60. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35.
61. Yuki N, Watanabe H, Nakajima T, Spath PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 2011; 82: 87-91.
62. Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9: 431-8.
63. Mollnes TE, Hogasen K, De Carolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 1998; 48: 312-7.
64. Mouzaki A, Theodoropoulou M, Gianakopoulos I, Vlaha V, Kyrtsonis MC, Maniatis A. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 2002; 100: 1774-9.
65. Toungouz M, Denys C, Dupont E. Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins. Transplantation 1996; 62: 1292-6.
66. Ramisse F, Deramoudt FX, Szatanik M, et al. Effective prophylaxis of influenza A virus pneumonia in mice by topical passive immunotherapy with polyvalent human immunoglobulins or F(ab')2 fragments. Clin Exp Immunol 1998; 111: 583-7.
67. Toungouz M, Denys CH, De Groote D, Dupont E. In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 1995; 89: 698-703.
68. Sell S, Fahey JL. Relationship between Gamma-Globulin Metabolism and Low Serum Gamma-Globulin in Germfree Mice. J Immunol 1964; 93: 81-7.
69. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 2009; 88: 1-6.
70. Aukrust P, Froland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994; 84: 2136-43.
71. Aukrust P, Muller F, Svenson M, Nordoy I, Bendtzen K, Froland SS. Administration of intravenous immunoglobulin (IVIG) in vivo-down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999; 115: 136-43.
72. Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104 (Suppl 1): 10-20.
73. Macmillan HF, Rowter D, Lee T, Issekutz AC. Intravenous immunoglobulin G selectively inhibits IL-1alpha-induced neutrophilendothelial cell adhesion. Autoimmunity 2010; 43: 619-27.
74. von Gunten S, Simon HU. Cell death modulation by intravenous immunoglobulin. J Clin Immunol 2010; 30 Suppl 1: S24-30.
75. Prasad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161: 3781-90.
76. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
77. Dalakas M. IVIg in other autoimmune neurological disorders: current status and future prospects. J Neurol 2008; 255 Suppl 3: 12-6.
78. Katz U, Kishner I, Magalashvili D, Shoenfeld Y, Achiron A. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity 2006; 39: 513-7.
79. Magga J, Puli L, Pihlaja R, et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 2010; 7: 90.
80. Niimi N, Kohyama K, Kamei S, Matsumoto Y. Intravenous immunoglobulin therapy prevents development of autoimmune encephalomyelitis and suppresses activation of matrix metalloproteinases. Neuropathology 2010;
81. Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response. Lupus 1999; 8: 705-12.
82. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005; 29: 219-28.
83. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum 2004; 34: 593-601.
84. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 2005; 38: 473-85.
85. Zandman-Goddard G, Krauthammer A, Shoenfeld Y. The steroidsparing effect of intravenous immunoglobulin in patients with autoimmune diseases. Expert Rev Clin Immunol 2007; 3: 773-80.
86. Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 2008; 10: 55-7.
87. Levy Y, Uziel Y, Zandman G, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci 2005; 1051: 779-86.
88. Takahashi Y, Takata T, Hoshino M, Sakurai M, Kanazawa I. Benefit of IVIG for long-standing ataxic sensory neuronopathy with Sjogren's syndrome. IV immunoglobulin. Neurology 2003; 60: 503-5.
89. De Carolis C, Perricone C, Perricone R. NK cells, autoantibodies, and immunologic infertility: a complex interplay. Clin Rev Allergy Immunol 2010; 39: 166-75.
90. Vaitla PM, McDermott EM. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford) 2010; 49: 1040-8.
91. Perricone R, De Carolis C, Kroegler B, et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology (Oxford) 2008; 47: 646-51.
92. Triolo G, Ferrante A, Accardo-Palumbo A, et al. IVIG in APS pregnancy. Lupus 2004; 13: 731-5.
93. Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. Int J Gynaecol Obstet 2009; 104: 223-5.
94. Stephenson MD, Kutteh WH, Purkiss S, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Hum Reprod 2010; 25: 2203-9.
95. Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62: 1147-52.
96. Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 2009; 42: 553-60.
97. Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the CAPS Registry. J Autoimmun 2009; 32: 240-5.
98. Nacci F, Righi A, Conforti ML, et al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study. Ann Rheum Dis 2007; 66: 977-9.
99. Amital H, Rewald E, Levy Y, et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 2003; 62: 175-7.
100. Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum 2004; 50: 1005-7.
101. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2010; 38: 186-95.
102. Baum S, Scope A, Barzilai A, Azizi E, Trau H. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 548-52.
103. Zandman-Goddard G. Intravenous immunoglobulin and autoimmunity. Isr Med Assoc J 2010; 12: 45-6.
104. Efthimiou P, Kontzias A, Ward CM, Ogden NS. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol 2007; 3: 328-35.
105. Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1994; 21: 2353-8.
106. Kim HA, Sung JM, Suh CH. Therapeutic responses and prognosis in adult-onset Still's disease. Rheumatol Int 2011;
107. Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)-- beyond immunodeficiencies and neurology. Clin Exp Immunol 2009; 158 (Suppl 1): 23-33.
108. Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum 2008; 58: 308-17.
109. Pras E, Neumann R, Zandman-Goddard G, et al. Intraocular inflammation in autoimmune diseases. Semin Arthritis Rheum 2004; 34: 602-9.
110. Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Behcet's disease. Br J Ophthalmol 2001; 85: 1287-8.
111. Donofrio PD, Berger A, Brannagan TH, 3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 2009; 40: 890-900.
112. Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant 2011; 11: 196-202.
113. Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev 2010; 24 (Suppl 1): S7-S27.
114. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6: 257-9.
115. Kumar A, Teuber SS, Gershwin ME. Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol 2006; 140: 185-98.